VistaGen Therapeutics Inc. (NASDAQ:VTGN) shares, rose in value on Friday, 05/13/22, with the stock price up by 3.64% to the previous day’s close as strong demand from buyers drove the stock to $1.14.
Actively observing the price movement in the last trading, the stock closed the session at $1.10, falling within a range of $1.08 and $1.18. The value of beta (5-year monthly) was 0.98. Referring to stock’s 52-week performance, its high was $3.55, and the low was $1.06. On the whole, VTGN has fluctuated by -34.10% over the past month.
With the market capitalization of VistaGen Therapeutics Inc. currently standing at about $261.39 million, investors are eagerly awaiting this quarter’s results, scheduled for Feb 09, 2022 – Feb 14, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.07, which is expected to increase to -$0.07 for fiscal year -$0.25 and then to about -$0.35 by fiscal year 2023. Data indicates that the EPS growth is expected to be 49.00% in 2023, while the next year’s EPS growth is forecast to be -40.00%.
Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $1.22 million, representing an increase of 12.00% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that VTGN’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
4 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 3 recommend it as a Buy and 1 called the VTGN stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of VTGN currently trading nearly -14.57% and -11.17% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.17, while the 7-day volatility ratio is showing 9.52% which for the 30-day chart, stands at 8.93%. Furthermore, VistaGen Therapeutics Inc. (VTGN)’s beta value is 0.94, and its average true range (ATR) is 0.13.
A comparison of VistaGen Therapeutics Inc. (VTGN) with its peers suggests the former has fared considerably weaker in the market. VTGN showed an intraday change of 3.64% in last session, and over the past year, it shrunk by -46.73%%. In comparison, Iovance Biotherapeutics Inc. (IOVA) has moved higher at 12.20% on the day and was down -45.51% over the past 12 months. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 2.39%. Meanwhile, the Dow Jones Industrial Improved by 1.47%.
Data on historical trading for VistaGen Therapeutics Inc. (NASDAQ:VTGN) indicates that the trading volumes over the past 10 days have averaged 1.03 million and over the past 3 months, they’ve averaged 1.53 million. According to company’s latest data on outstanding shares, there are 202.33 million shares outstanding.
Nearly 0.10% of VistaGen Therapeutics Inc.’s shares belong to company insiders and institutional investors own 71.80% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 11.69 million shares as on Jan 30, 2022, resulting in a short ratio of 10.04. According to the data, the short interest in VistaGen Therapeutics Inc. (VTGN) stood at 5.86% of shares outstanding as of Jan 30, 2022; the number of short shares registered in Dec 30, 2021 reached 11.17 million. The stock has fallen by -41.54% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VTGN stock heading into the next quarter.